AAAAAA
Results:
1-11
|
Results: 11
Authors:
Paietta, E
Neuberg, D
Richards, S
Bennett, JM
Han, L
Racevskis, J
Dewald, G
Rowe, JM
Wiernik, PH
Citation: E. Paietta et al., Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity, AM J HEMAT, 66(3), 2001, pp. 189-196
Authors:
Bennett, JM
Young, MS
Liesveld, JL
Paietta, E
Miller, KB
Lazarus, HM
Marsh, RD
Friedenberg, WR
Saba, HT
Hayes, FA
Dewald, GW
Hiddemann, W
Rowe, JM
Citation: Jm. Bennett et al., Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group study, AM J HEMAT, 66(1), 2001, pp. 23-27
Authors:
Wiernik, PH
Ashwin, M
Hu, XP
Paietta, E
Brown, K
Citation: Ph. Wiernik et al., Anticipation in familial chronic lymphocytic leukaemia, BR J HAEM, 113(2), 2001, pp. 407-414
Authors:
Gordon, MS
Young, ML
Tallman, MS
Cripe, LD
Bennett, JM
Paietta, E
Longo, W
Gerad, H
Mazza, J
Rowe, JM
Citation: Ms. Gordon et al., Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia - A study of the Eastern Cooperative Oncology Group (ECOG), E5995, LEUK RES, 24(10), 2000, pp. 871-875
Authors:
Wiernik, PH
Wang, SQ
Hu, XP
Marino, P
Paietta, E
Citation: Ph. Wiernik et al., Age of onset evidence for anticipation in familial non-Hodgkin's lymphoma, BR J HAEM, 108(1), 2000, pp. 72-79
Authors:
Slovak, ML
Kopecky, KJ
Cassileth, PA
Harrington, DH
Theil, KS
Mohamed, A
Paietta, E
Willman, CL
Head, DR
Rowe, JM
Forman, SJ
Appelbaum, FR
Citation: Ml. Slovak et al., Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study, BLOOD, 96(13), 2000, pp. 4075-4083
Authors:
Murray, CK
Estey, E
Paietta, E
Howard, RS
Edenfield, WJ
Pierce, S
Mann, KP
Bolan, C
Byrd, JC
Citation: Ck. Murray et al., CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?, J CL ONCOL, 17(1), 1999, pp. 293-297
Authors:
Tallman, MS
Lee, S
Sikic, BI
Paietta, E
Wiernik, PH
Bennett, JM
Rowe, JM
Citation: Ms. Tallman et al., Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia - An Eastern Cooperative Oncology Group Pilot Study, CANCER, 85(2), 1999, pp. 358-367
Authors:
Advani, R
Saba, HI
Tallman, MS
Rowe, JM
Wiernik, PH
Ramek, J
Dugan, K
Lum, B
Villena, J
Davis, E
Paietta, E
Litchman, M
Sikic, BI
Greenberg, PL
Citation: R. Advani et al., Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar), BLOOD, 93(3), 1999, pp. 787-795
Authors:
Paietta, E
Racevskis, J
Bennett, JM
Neuberg, D
Cassileth, PA
Rowe, JM
Wiernik, PH
Citation: E. Paietta et al., Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience, LEUKEMIA, 12(12), 1998, pp. 1881-1885
Authors:
Cassileth, PA
Harrington, DP
Appelbaum, FR
Lazarus, HM
Rowe, JM
Paietta, E
Willman, C
Hurd, DD
Bennett, JM
Blume, KG
Head, DR
Wiernik, PH
Citation: Pa. Cassileth et al., Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission, N ENG J MED, 339(23), 1998, pp. 1649-1656
Risultati:
1-11
|